NCT02314169 2026-04-22
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Centre Hospitalier Universitaire de Besancon